Welcome to our dedicated page for Affimed N.V. news (Ticker: AFMD), a resource for investors and traders seeking the latest updates and insights on Affimed N.V. stock.
Affimed N.V. (Nasdaq: AFMD) is a clinical-stage biopharmaceutical company headquartered in Mannheim, Germany, with additional offices in New York, NY. Affimed is dedicated to leveraging the power of the innate immune system to develop innovative immuno-oncology therapies primarily aimed at treating various cancers. The company is at the forefront of developing its proprietary innate cell engagers (ICE®), which are designed to target and eliminate both hematologic and solid tumors.
At the core of Affimed's innovation is their ROCK® platform, a state-of-the-art technology that generates customized ICE® molecules. These molecules harness the natural power of immune cells, such as natural killer (NK) cells and T-cells, to target and destroy cancer cells. Affimed's lead products include AFM13 (acimtamig), AFM24, and AFM28, which are currently undergoing various stages of clinical trials.
AFM13, the company's flagship innate cell engager, shows promise in treating CD30-positive hematologic tumors. It has demonstrated significant clinical efficacy in heavily pretreated patients with refractory Hodgkin lymphoma, achieving high objective response rates (ORR) and complete response (CR) rates. AFM13 is being investigated in combination with NK cells in the LuminICE-203 study, with initial data expected in the first half of 2024.
AFM24 is another key candidate, targeting EGFR-expressing solid tumors. It is currently being tested in combination with atezolizumab, a checkpoint inhibitor, in the AFM24-102 Phase 1/2a study. Recent data showed a disease control rate of 73.3% in heavily pretreated patients with EGFR wild-type non-small cell lung cancer (NSCLC), including significant objective responses. The FDA has granted Fast Track designation for this combination therapy, highlighting its potential to meet unmet medical needs.
AFM28 targets CD123-positive acute myeloid leukemia (AML). Preclinical studies have shown that AFM28 can effectively reduce tumor growth and eliminate leukemic blasts and stem cells. The drug is currently in early clinical development, with future plans to test it in combination with allogeneic off-the-shelf NK cells.
Affimed is also committed to strategic collaborations and partnerships to advance its clinical programs. Notable collaborations include those with Artiva Biotherapeutics, The University of Texas MD Anderson Cancer Center, and Roche. These partnerships are aimed at enhancing the efficacy and safety profiles of Affimed's therapies and bringing innovative treatments to patients more quickly.
Despite facing challenges such as restructuring and a reduction in workforce, Affimed remains focused on advancing its clinical pipeline. The company's strong leadership team, extensive experience in biotechnology and pharmaceuticals, and a clear mission to revolutionize cancer treatment underscore its commitment to giving patients back their innate ability to fight cancer.
For more information about Affimed's people, pipeline, and ongoing projects, please visit www.affimed.com.
Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology firm, announced its participation in several investor conferences in September 2021. Notable events include the Citi’s 16th Annual BioPharma Virtual Conference on September 8, offering one-on-one meetings, and the 2021 Wells Fargo Virtual Healthcare Conference on September 9, featuring a presentation at 8:00 a.m. Eastern Time. Additional meetings will take place at the Morgan Stanley Global Healthcare Conference and Cantor Fitzgerald Virtual Global Healthcare Conference. For inquiries or to schedule meetings, contact Alex Fudukidis.
Affimed N.V. (Nasdaq: AFMD) will release its second quarter 2021 financial results on September 8, 2021, followed by a conference call at 8:30 a.m. EDT. The call aims to discuss the financial results and recent corporate developments. Interested parties can access the call via phone or webcast, with details provided for both U.S. and international callers. Affimed focuses on immuno-oncology, leveraging its proprietary ROCK® platform to develop targeted treatments against various tumors. A replay of the call will be available for 30 days post-event.
Affimed N.V. (Nasdaq: AFMD) announces significant findings regarding its innate cell engager, AFM24, targeting EGFR-expressing tumors. Preclinical data highlight AFM24’s ability to engage the innate immune system effectively, emphasizing its unique mechanism that operates independently of EGFR mutations. Notably, toxicity studies in cynomolgus monkeys revealed a favorable safety profile at doses up to 75 mg/kg. These results bolster AFM24's potential in the ongoing Phase 1/2a study for patients with advanced solid tumors, reflecting promising advancements in immuno-oncology.
Affimed N.V. (Nasdaq: AFMD) reported strong financial results for Q1 2021, with total revenue reaching €11.7 million, up from €5.1 million year-over-year. The company's cash and cash equivalents stood at €240.7 million, ensuring operations through the second half of 2023. Key clinical updates include positive interim results for AFM13 in PTCL and a 100% response rate in a combination therapy trial with NK cells. Comprehensive plans for upcoming trials of AFM24 and AFM28 show promise for further development. A conference call is scheduled for July 1, 2021, to discuss these results.
Affimed N.V. (Nasdaq: AFMD) will release its first-quarter 2021 financial results on July 1, 2021. A conference call will occur at 8:30 a.m. EDT to discuss these results and recent corporate developments. Stakeholders can access the call via phone or live audio webcast. Additionally, the company's innovative ROCK® platform aims to enhance cancer treatment through the innate immune system, positioning Affimed as a leader in immuno-oncology with a clinical-stage ICE®. Further information is available on their website.
Affimed N.V. (Nasdaq: AFMD) announced the appointment of Ms. Uta Kemmerich-Keil to its Supervisory Board, effective immediately from June 15, 2021. Approved during the Annual General Meeting, her extensive experience in the life sciences sector, particularly in leading global pharmaceutical companies, positions her to provide significant guidance in advancing Affimed's immuno-oncology pipeline. Kemmerich-Keil previously held senior roles at companies like P&G and Merck KGaA, bringing valuable financial and strategic expertise to Affimed’s growth strategy.
Affimed N.V. (Nasdaq: AFMD) announced that its CEO, Dr. Adi Hoess, will present at the Jefferies Virtual Healthcare Conference on June 2, 2021, at 8:30 a.m. Eastern Time.
A live webcast can be accessed on Affimed’s website, with an archived replay available for 30 days post-event.
Affimed is focused on immuno-oncology and utilizes its proprietary ROCK® platform to harness the innate immune system in cancer treatment, developing innovative therapies to target various tumors.
Affimed N.V. (Nasdaq: AFMD) announced that its 2021 Annual General Meeting (AGM) will take place on June 15, 2021, at 17:30 PM CET (11:30 AM EDT). In light of the ongoing COVID-19 pandemic, the meeting will be held virtually to ensure the safety of shareholders. Interested parties can access the meeting via the designated link. The notice and agenda for the meeting are accessible on the company’s website and the SEC’s website.
Affimed N.V. (Nasdaq: AFMD) announced promising preclinical results for AFM13, an innate cell engager (ICE®) targeting CD30-positive tumors. The data showed that AFM13 enhanced the efficacy of natural killer (NK) cells in recognizing and killing tumor cells both in vitro and in vivo. This supports the ongoing Phase I clinical trial of AFM13 pre-complexed with NK cells. Notably, early Phase 1 data revealed a 100% objective response rate among heavily pretreated patients, with no severe side effects reported. These findings highlight AFM13's potential as an innovative cancer treatment.
Affimed N.V. (Nasdaq: AFMD) reported positive interim results for its AFM13 monotherapy study in PTCL, achieving a 100% objective response rate in four evaluable patients, including two complete responses. The company also provided updates on clinical trials for AFM24, including a cleared IND application for its combination with NKGen's SNK-01. Financially, Affimed showed a pro forma cash position of approximately €244.5 million as of December 31, 2020, which supports operations through mid-2023. Total revenue rose to €28.4 million in 2020, driven largely by collaborations with Genentech and Roivant.
FAQ
What is the current stock price of Affimed N.V. (AFMD)?
What is the market cap of Affimed N.V. (AFMD)?
What does Affimed N.V. specialize in?
What is the ROCK® platform?
What are Affimed's key clinical candidates?
What is AFM13 used for?
What is the significance of AFM24's Fast Track designation?
How does AFM28 work?
What collaborations does Affimed have?
Where is Affimed N.V. headquartered?
What are the recent achievements of Affimed?
What is the company's mission?
